Cytotoxic chemotherapy is effective in debulking tumour masses initially; however, in some patients tumours become progressively unresponsive after multiple treatment cycles. Previous studies have demonstrated that cancer stem cells (CSCs) are selectively enriched after chemotherapy through enhanced survival [1] [2] [3] . Here we reveal a new mechanism by which bladder CSCs actively contribute to therapeutic resistance via an unexpected proliferative response to repopulate residual tumours between chemotherapy cycles, using human bladder cancer xenografts. Further analyses demonstrate the recruitment of a quiescent label-retaining pool of CSCs into cell division in response to chemotherapy-induced damages, similar to mobilization of normal stem cells during wound repair [4] [5] [6] [7] . While chemotherapy effectively induces apoptosis, associated prostaglandin E 2 (PGE 2 ) release paradoxically promotes neighbouring CSC repopulation. This repopulation can be abrogated by a PGE 2 -neutralizing antibody and celecoxib drug-mediated blockade of PGE 2 signalling. In vivo administration of the cyclooxygenase-2 (COX2) inhibitor celecoxib effectively abolishes a PGE 2 -and COX2-mediated wound response gene signature, and attenuates progressive manifestation of chemoresistance in xenograft tumours, including primary xenografts derived from a patient who was resistant to chemotherapy. Collectively, these findings uncover a new underlying mechanism that models the progressive development of clinical chemoresistance, and implicate an adjunctive therapy to enhance chemotherapeutic response of bladder urothelial carcinomas by abrogating early tumour repopulation.
Cytotoxic chemotherapy remains the standard of care for many advanced carcinomas. Although chemotherapy is effective in debulking tumour mass, certain patients show initial response but progressively become unresponsive after multiple treatments. Chemotherapy is administered in cycles to induce fractionated killing of unsynchronized proliferating cancer cells, and treatments are spaced out to allow recovery of normal tissues between cycles 8 . However, repopulation of residual surviving cancer cells also occurs, which is an undesirable phenomenon that limits chemotherapeutic response in subsequent cycles 8 . Recent studies demonstrated that CSCs have a survival advantage in response to chemotherapy [1] [2] [3] . Here we investigate the unexplored concept that CSCs may actively proliferate in response to chemotherapy-induced damages, similar to how tissue resident stem cells mobilize to wound sites during tissue repair [4] [5] [6] [7] 9 . Bladder urothelial carcinomas contain cells that span various cellular differentiation stages [10] [11] [12] [13] [14] [15] , cytokeratin 14 (CK14) marks the most primitive (or least differentiated) cells 11, 13 and patients with abundant CK14 staining correlate with poor survival 11, 13 . Here, comparative analysis of matching pre-and post-chemotherapy patient tissues revealed one group with CK14 staining enrichment/persistence ( Fig. 1a and Extended Data Fig. 1a-c ) and another group with no CK14 staining after chemotherapy ( Fig. 1a and Extended Data Fig. 1a, b, d ). Kaplan-Meier analysis revealed patients with CK14
1 cancer cell enrichment/persistence showed worse survival (Fig. 1a) , justifying further need to investigate their chemotherapeutic response. Using the standard chemotherapy regimen for advanced bladder urothelial carcinomas (that is, gemcitabine and cisplatin (GC)), one chemotherapy cycle effectively reduced the growth rate of all xenograft tumours in comparison to controls (Fig. 1b and Extended Data Fig. 2a) , while leading to a generalized enrichment of CK14 1 cancer cells (1.7-4.3-fold) (Fig. 1c, d and Extended Data Fig. 2b, c) . This enrichment is unexpectedly contributed by proliferation marked by mitosis phase protein phospho-histone H3 (Extended Data Fig. 2d , e; white arrows). In addition to the conventional thinking that chemotherapy selects for chemoresistant cancer cells, this active proliferative response may represent a new mechanism contributing to repopulation of residual tumours. To investigate this phenomenon further, we constructed a lentiviral reporter to enable prospective isolation of CK14 1 cells by fluorescence activated cell sorting (FACS), as CK14 is an intracellular protein that would not allow for cell surface antibody labelling. We subcloned a previously validated gene promoter region of human KRT14 (ref. 16 ) into a promoterless lentiviral vector carrying a tdTomato (hK14. tdTomato) red fluorescent protein (Extended Data Fig. 3a ). With this reporter stably transduced into urothelial carcinoma cells ( Fig. 1e and Extended Data Fig. 3b-d) , we could readily detect a tdTomato 1 (Tm 1 ) subpopulation that exclusively expressed CK14 at the protein ( Fig. 1f ; white arrows) and messenger RNA ( Fig. 1g; KRT14 ) levels, while minimally expressing the differentiation marker uroplakin 1B ( Fig. 1g; UPK1B) . These Tm 1 CK14 1 urothelial carcinoma cells represented a subpopulation of our previously reported CD44 1
CD49f
1 CSCs 11,13 (Extended Data Fig. 3b-d) . Additional functional evaluation validated their unique biological properties being enriched for sphere-forming stem cells in vitro (Extended Data Fig. 3e ) and tumorigenic cells when engrafted in vivo (Extended Data Fig. 3f Fig. 4 ). Concurrent cell cycle analyses revealed an unexpected proliferative response of both subpopulations by entering into S phase at days 2 and 3, respectively (Fig. 1i, j and Extended Data Fig. 5 ). Interestingly, Tm 2 CK14 2 cancer cells remained proliferative throughout the 11-day time course, whereas Tm 1 CK14 1 cancer cells gradually returned to a less proliferative state (Fig. 1i, j and Extended Data Fig. 5 ). Because gemcitabine (a cytidine analogue) and cisplatin preferentially incorporate into proliferating cells to initiate apoptosis via inducing DNA crosslinks, strand breaks and adduct formation 17 , we propose that the slower cycling properties of CK14 1 cells may provide one mechanism by which they evade GC chemotherapy.
To explore this hypothesis in vivo, we used the classical pulse-chase labelling approach to mark quiescent cells 18, 19 , followed by chemotherapy treatment to analyse their proliferative response (Fig. 2a) . We repetitively pulsed xenograft tumours with the thymidine analogue 5-iodo-29-deoxyuridine (IdU), followed by a 4-8-week chase period, during which dividing cells diluted out IdU whereas quiescent cells retained IdU 18 ( Fig. 2a) . Effective IdU pulsing was validated (Extended Data Fig. 6a ) and a quiescent cancer subpopulation (1.08-5.48%) was consistently found (Extended Data Fig. 6a-d) , which we term label-retaining cancer cells (LRCCs) (green cells in Fig. 2b, Extended Data Fig. 6a, b) . These IdU 1 LRCCs predominately localized within CK14 1 cells (Fig. 2b , c; red) and were mutually exclusive to proliferating cells labelled by 5-chloro-29-deoxyuridine (CldU) ( Fig. 2b ; white) or other proliferation markers (Extended Data Fig. 6e-g ). Notably, chemotherapy significantly reduced the fraction of CldU 1 proliferating cells while not altering IdU 1 LRCCs initially ( Fig. 2d , e; 6 h). These results confirmed our in vitro findings that gemcitabine and cisplatin preferentially induce apoptosis of dividing cells 17 (Fig. 1h, i ). This is paradoxically followed by a significant increase in IdU 1 LRCCs that were simultaneously incorporated with CldU ( Fig. 2d, e; 12 h ). These IdU 1 CldU 1 cells constantly appeared as a two-cell state immediate adjacent to each other ( Fig. 2d ; yellow cells), suggestive of LRCC recruitment to divide after chemotherapy-induced apoptotic damage. This trend coincided with an increase in CldU 1 proliferating and CK14 1 cancer cells ( Fig. 2e and Extended Data Fig. 6h ;12 h), which gradually decreased from 24 h and onwards, corresponding with a plateau of single CldU 1 proliferating cancer cells (Fig. 2e) . Collectively, these results illustrate that quiescent LRCCs are unexpectedly recruited into cell division after chemotherapy treatment, contributing to repopulation of residual tumours.
Next, we explored the molecular mechanisms underlying tumour repopulation. After chemotherapy, it is known that soluble factors are released from apoptotic cells to attract immune cells for clearance 20 . Paradoxically, some of these factors are also known to stimulate epithelial cell proliferation during wound repair. One example is PGE 2 , which was demonstrated to promote stem-cell expansion 21 and mobilization 22 . ), and CK14 1 cancer cells (white) at various time after chemotherapy (n 5 4 xenografted tumours). All data represent mean 6 s.e.m. *P , 0.05, **P , 0.01 (one-way analysis of variance (ANOVA) followed by Dunnett's test for multiple comparisons). Scale bars, 50 mm.
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Here, we investigate PGE 2 and CSCs in the context of chemotherapy, which was not studied previously. Urothelial carcinoma cells were exposed to chemotherapy in vitro (Fig. 3a) and their viability was quantified by flow cytometry analyses of mitochondrial and plasma membrane permeability ( Fig. 3b) and by cleaved caspase-3 (CASP3) (Fig. 3c) . The time kinetics of chemotherapy-induced apoptosis (Fig. 3b, c ) is closely associated with an increase in the expression of COX2 (the enzyme mediating PGE 2 production) and PGE 2 release (Fig. 3d) . We further validated these findings in vivo, by analysing the co-localization of PGE 2 , CASP3 and CK14
1 cancer cells, and their associated changes after chemotherapy (Fig. 3e, f) . Similar to in vitro, chemotherapy induced apoptosis as measured by a CASP3-positive stain, which peaked at 6 h and gradually reduced thereafter (Fig. 3e, f) , which was closely followed by PGE 2 release from 6 to 24 h after chemotherapy (Fig. 3f) . Furthermore, PGE 2 localization ( Fig. 3e ; red) was often found adjacent to CK14 1 cancer cells ( Fig. 3e; green) . Altogether, these findings demonstrated that chemotherapy-induced apoptosis is closely followed by the release of PGE 2 , which preceded that of tumour repopulation (Fig. 3g) .
To establish a biological role for PGE 2 in promoting tumour repopulation, we investigated how exogenous dmPGE 2 (a stabilized PGE 2 analogue) could modulate sphere-forming stem cells in vitro 23 . Exogenous dmPGE 2 treatment significantly increased the frequency of sphereforming cells (Fig. 3h) . To evaluate PGE 2 in the context of chemotherapy, we applied PGE 2 -containing supernatant obtained from chemotherapytreated cells to urothelial carcinoma cells (Fig. 3a) , and compared their sphere-forming ability to those receiving exogenous dmPGE 2 (Fig. 3i) . Although both conditions significantly induced sphere-forming cells, supernatant from chemotherapy-treated cells induced a higher frequency (Fig. 3i) . Notably, functional blockade of PGE 2 by a neutralizing antibody significantly reduced the ability of factor-containing supernatant to generate sphere-forming cells (Fig. 3i) . Furthermore, the addition of the pharmacological COX2 inhibitor celecoxib, alone or in combination with a PGE 2 neutralizing antibody, further reduced their frequencies (Fig. 3i) .
Because more than 70% of patients with advanced bladder cancer do not benefit from neoadjuvant chemotherapy [24] [25] [26] , and celecoxib is a US Food and Drug Administration (FDA)-approved drug, we evaluated whether the attenuation of PGE 2 signalling in vivo could enhance chemotherapeutic response (Fig. 4a) . Although chemotherapy is clinically administered in multiple cycles, few preclinical studies administered chemotherapy beyond one cycle or a single dose. To bridge this gap, we recapitulated the clinical regimen ( Fig. 4a-e) in advanced bladder cancer xenografts, including one derived from a patient who was resistant to chemotherapy ( Fig. 4e and Extended Data Fig. 1a) . During the first chemotherapy cycle, both PDX-3 and T24 xenograft lines were responsive to chemotherapy (GC) and combination therapy (celecoxib plus GC) by reducing tumour size ( Fig. 4b, e; days 3-12) . Nevertheless, celecoxib combination treatment did abrogate notable expansion of CK14 1 cancer cells induced by chemotherapy (Extended Data Fig. 7a-c) . Remarkably, manifestation of chemoresistance occurred progressively after successive chemotherapy cycles ( Fig. 4b, e ; black circle), and celecoxib combination treatment (celecoxib plus GC) enhanced chemotherapeutic response more evidently in later treatment cycles ( Fig. 4b, e ; asterisk). T24 bladder cancer xenografts were limited to two chemotherapy cycles owing to distal lung metastases, and celecoxib combination treatment significantly diminished metastatic lung foci (Fig. 4c, d ). Because celecoxib is known to suppress prostacyclin and predisposes patients to thrombosis 27 , patients with cancer prescribed celecoxib as adjuvant therapy will probably be co-administered with low-dose aspirin for cardioprotection. We confirmed the antithrombotic efficacy of low-dose aspirin without affecting the overall efficacy of celecoxib (Extended Data  Fig. 8) .
Here, our findings highlight a new mechanism by which CK14 1 CSCs contribute to the progressive development of chemoresistance, via their proliferative response to fuel repopulation of residual tumours during the gap periods between chemotherapy cycles (Extended Data Fig. 10 ). Global gene expression profiling further revealed a parallel to tissue wound response, that chemoresistant tumours elicited enrichment of a 'wound-response gene signature' (Fig. 4f, g and Extended Data Fig. 9a, b) , which could be abrogated by combination celecoxib treatment (Fig. 4h and Extended Data Fig. 9c ). The PTGS2 gene, which encodes COX2 and is a core pathway component for PGE 2 signalling, is among these wound-response genes (Fig. 4g, h ). Similar findings were found in human bladder carcinomas that are resistant to chemotherapy (Fig. 4f and Extended Data Fig. 9a, d, e) , thus confirming the importance and generalization of PGE 2 /COX2 signalling during development of chemoresistance, while other metabolites of the arachidonic acid pathway may also be involved. By validating the efficacy of celecoxib in abrogating chemoresistance in xenografts derived from a patient who was resistant to chemotherapy, this preclinical finding provides considerable implications for immediate clinical translation, as the standard of care All data represent mean 6 s.e.m. *P , 0.05, ***P , 0.001 (Student's t-test (h) and one-way ANOVA followed by Dunnett's test for multiple comparisons (i)). Scale bars, 100 mm.
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for advanced bladder cancers is limited to cytotoxic chemotherapy and surgery with no other therapeutics [28] [29] [30] . This approach to abrogate chemoresistance may extend to other epithelial tumour types on further functional validation.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. PLEK  HNF4A  VIL1  XCR1  COL3A1  DEFB1  SCN9A  EDNRA  GUCY1A2  SPRR3  F2RL2  EGF  SCUBE1  DGK1  GYP4F2  HGF  HOPX  IGFBP1  P2RX1  P2RX1  MASP1  AIM2  FGG  LY96  VAV1  PTGS2  FGA  EDN1  AOAH  CYBB   CCR4  PTGS2  HBE1  NLRP3  PDE3A  KIF4B  EDNRA  PF4  LBP  PTGER4  TAC1  F13A1  CD244  IL36G  BMP6  CDO1  ADRA2A  IL2RA  SIRPG  CD177  IFNA1  TRPC3  PIK3R6  PDE1A  CAV3  SAA4  PATE4  EDNRB  SCUBE1  C4BPB  SPP1  NOS1  CCR1  PIK3R5  SLC8A3  CYP1A1 of each GC chemotherapy cycle. f, Gene set enrichment analysis (GSEA) validated enrichment of 'wound-response gene signature' after chemotherapy in patients with bladder cancer classified as non-responders. NES, normalized enrichment score. g, GSEA revealing enrichment of wound-response gene signature in chemotherapy-treated bladder cancer xenografts. Heat map demonstrating genes within leading edge, including PTGS2 (encoding COX2), a core pathway component for PGE 2 . h, GSEA and heat map highlighting abrogation of wound-response gene signature after celecoxib combination treatment. All data represent mean 6 s.e.m. Tumour volume measurements are relative to mean tumour volume at day 0. *P , 0.05, **P , 0.01 (one-way ANOVA followed by Dunnett's test for multiple comparisons). Data Fig. 1a) were obtained with patient consent under Institutional Review Board (H-25099) approval at Baylor College of Medicine. Tumour tissues were subdivided into 2-5 mm 3 pieces, coated with growth-factor-reduced matrigel (BD) and media in a 1:1 ratio, and embedded within the subcutaneous space underneath the skin of mice (male or female, 6-8 weeks old). Successfully xenografted tumours were then enzymatically dissociated into single cell suspensions and directly passaged in vivo without prior culturing in vitro, as previously reported 10, 11 . Animal work was performed in accordance to ethical regulations approved by Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC; AN-5803). In vitro treatment. Immortalized bladder cancer cell line T24 (high-grade) was purchased from ATCC and maintained in DMEM (HyClone), supplemented with 10% FBS (Gibco) and penicillin-streptomycin (Cellgro). Cells used were authenticated and tested for mycoplasma at the Tissue and Cell Culture Core Laboratory at Baylor College of Medicine. Cells were incubated with gemcitabine (7.5 ng ml
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21
; Sigma) 2 h before addition of cisplatin (100 mg ml
; Sigma). Determination of cell viability after treatment was based on the analysis of mitochondrial transmembrane potential by 3,39-dihexyloxacarbocyanine iodide (DiOC 6 ; Molecular Probes, Invitrogen) and cell membrane permeability to propidium iodide (Sigma) by FACS (BD Fortessa) at the indicated time points (24, 48 and 72 h). CASP3 cleavage was measured at the indicated time points using standard immunoblotting with rabbitpolyclonal CASP3 antibody (Cell Signaling, 9662; 1:1,000), COX2 expression was measured with rabbit-polyclonal COX2 antibody (Cell Signaling, 4842; 1:1,000), GAPDH expression was measured with mouse-monoclonal GAPDH antibody (Santa Cruz Biotechnology, sc-137179; 1:400). Appropriate secondary antibodies (antirabbit/mouse IgG, horseradish peroxidase (HRP)-linked antibody, Cell Signaling; 1:2,000) were used for detection. In vivo treatment. When xenograft tumours reached a palpable size, mice (male and female) were assigned into different experimental groups: vehicle control (12.5% dimethylsulphoxide (DMSO) in saline) group; GC chemotherapy treatment group; celecoxib treatment group; and celecoxib plus GC combinatory treatment group. According to the Institutional Animal Care and Use Committees (IUCUC) protocol (AN-5803), the maximal allowable size of the tumours could not exceed 10% of mouse body weight. For systemic administration of a single GC treatment, mice were treated with either vehicle or sequential intraperitoneal injection of gemcitabine (60 mg kg
) and cisplatin (6 mg kg 21 ) given 4 h apart. For one GC cycle, cisplatin (6 mg kg 21 ) was only applied after the first gemcitabine (40 mg kg 21 ) treatment on day 2, followed by three consecutive treatments of gemcitabine on days 5, 8 and 11 (GCRGRGRG). The tumours were collected 24 h after the last treatment. In celecoxib combination treatment experiments, mice were pretreated with celecoxib (5 mg kg 21 daily; Sigma PZ0008) via intraperitoneal injection 2 days before the initiation of chemotherapy, followed by daily intraperitoneal administration of celecoxib during chemotherapy or vehicle treatment cycle. Immunohistochemical analysis of CK14 in patient samples. Immunohistochemical staining was performed using keratin 14 polyclonal antibody (Covance, PRB-155P; 1:1,000). Every sample was scored for its CK14 staining by determining the percentage of visual fields that were CK14 negative (0%), CK14 low-infiltrating (,25%), CK14 high-infiltrating (25-100%), and CK14 basal-restricted (staining restricted to the basal layer of urothelium). The final result for each case was the average score of all visual fields. COX2 staining was performed on serial sections using COX2 monoclonal antibody (Cayman Chemical, 160112; 1:100). Immunofluorescence analyses. Tumour sections were analysed following standard haematoxylin and eosin procedures or immunostaining protocols as previously reported 10 . Nikon microscopy and NIS element software were used for imaging and quantification. Primary antibodies used are listed as follows: 5-bromo-29-deoxyuridine (BrdU) (for IdU, BD 347580; 1:100), BrdU (BD 347583, 1:100), BrdU (for CldU, Abcam, ab6326, 1:100), CK14 (Covance, PRB-155P, 1:1,000), CK14 (Abcam, ab77684, 1:100), cleaved CASP3 (Cell Signaling, 9661; 1:400), PGE 2 (Abcam, ab2318; 1:100), and phospho-histone H3 (Cell Signaling, 3377; 1:1,000). Generation of hK14.tdTomato lentiviral reporter construct. We developed a lentiviral construct that reports on the activity of human KRT14 promoter by subcloning a previously characterized and validated promoter region of human KRT14 (ref. 16 ) (obtained from ATCC, MBA-124) using EcoRI and BamHI restriction enzymatic digestion, and inserting this promoter fragment into a promoterless lentiviral vector (Clontech, 631754) tagged with a DD-tdTomato (Tm) red fluorescent protein (Clontech Lenti-X DD-tdTomato vector). DD-Tm protein is rapidly targeted to proteasome degradation unless incubated with Shield1 (Clontech) in vitro. Limiting dilution analysis of tumour subpopulations. For in vivo limiting dilution assay, Tm 1 CK14 1 and Tm 2 CK14 2 tumour cells were purified by FACS (BD FACS Aria Sorter) and serially diluted to the appropriate cell dose. Cells were injected and the number of tumours formed from each cell dose injected was scored. The frequency of cancer stem cells had been calculated using the ELDA software (http://bioinf.wehi.edu.au/software/elda/index.html) provided by the Walter and Eliza Hall Institute. qRT-PCR. RNA isolation (RNAspin Mini, Illustra, GE Healthcare) and reverse transcription (Superscript III First-Strand Synthesis, Invitrogen) were performed according to the manufacturer's instructions. We used Taqman Gene Expression assay mix (Applied Biosystems) and FAM-labelled Taqman probes to detect expression of the following genes: KRT14 (Applied Biosystems, Hs00265033_m1) and UPK1B (Applied Biosystems, Hs00199583_m1). Relative qPCR (DDC t method) was performed in triplicate using ABI Prism 7000 Sequence Detection System (Applied Biosystems). Gene expression levels were normalized to GAPDH transcript levels (Applied Biosystems, Hs99999905_m1). Cell cycle analysis. Tm 1 and Tm 2 cells subjected to in vitro GC chemotherapy were collected using trypsin (Gibco), washed twice with PBS and fixed with 70% ethanol for 30 min at room temperature. Cells were stained with propidium iodide (25 mg ml 21 solution in 4 mM citrate buffer supplemented with RNase, 10% Triton X-100 and PEG 6000; all from Sigma) and analysed by FACS (gating strategy excluded cell doublets from analysis). Dual labelling of slow-cycling and active-proliferating cancer cells. Mice were labelled by intraperitoneal injection of IdU (Sigma-Aldrich; 50 mg kg 21 bodyweight), BrdU (Sigma-Aldrich; 50 mg kg 21 bodyweight) or CldU (Sigma-Aldrich). For labelling of slow-cycling cells, repetitive pulsing of IdU (50mg kg 21 bodyweight) was given for 5 consecutive days, followed by various long chase periods (4-8 weeks) to localize LRCCs. For labelling of proliferating cells, CldU was given 1 h before tumour tissue collection to localize active cycling cancer cells. PGE 2 ELISA assay. To measure PGE 2 release, bladder cancer cells T24 were cultured in DMEM supplemented with 2% FBS and treated with gemcitabine (7.5 ng ml
; Sigma) and cisplatin (100 mg ml
; Sigma). Supernatants were collected 24, 48 and 72 h after treatment initiation. PGE 2 levels in the supernatants were measured by ELISA kit (R&D Systems). dmPGE 2 exogenous treatment. T24 cancer cells were plated in a semi-solid sphereforming assay in the presence of 0.38 ng ml 21 dmPGE 2 , 100 nM of neutralizing PGE 2 antibody (Cayman Chemical, 10009814), 5 mM celecoxib (Sigma) or vehicle for 12 days 23 . Clonal derivation of spheres from single cells was ensured and monitored as described 23 . Thromboprophylaxis with aspirin. Immunocompromised mice bearing T24 xenografted tumours were treated with celecoxib and GC chemotherapy in the presence or absence of aspirin (Sigma) (37.9 mg g 21 twice a week, equivalent of 162.5 mg daily dose in human) for two cycles, and antithrombotic activity of aspirin was tested by analysing tail bleeding time. In brief, tails of anaesthetized mice (1-3% isoflurane in 100% oxygen at a flow rate of 1-2 L min 21 ) were transected 1 mm from the tip with a scalpel, the remaining tail was immersed in 37 uC saline, and the time until bleeding stopped for more than 1 min was observed and recorded. RNA-sequencing. Tumour tissues were collected from the animals and snap-frozen in liquid nitrogen. RNA isolation was performed using Illustra RNAspin mini kit (GE Healthcare) upon manufacturer instructions. The Genomic and RNA Profiling Core at Baylor College of Medicine conducted sample quality checks using the NanoDrop spectrophotometer and Agilent Bioanalyzer 2100. A double-stranded DNA library was created using 1 mg of total RNA, preparing the fragments for hybridization onto a flowcell. First, cDNA was created using the fragmented 39 poly(A) selected portion of total RNA and random primers. Libraries were created from the cDNA by first blunt ending the fragments, attaching an adenosine to the 39 end and finally ligating unique adapters to the ends. The ligated products were then amplified using 15 cycles of PCR. The resulting libraries were quantitated using the NanoDrop spectrophotometer and fragment size assessed with the Agilent Bioanalyzer. A qPCR quantitation was performed on the libraries to determine the concentration of adaptor ligated fragments using a Bio-Rad iCycler iQ Real-Time PCR Detection System and a KAPA Library Quant Kit. Using the concentration from the Bio-Rad qPCR machine, 18 pM of library was loaded onto a flowcell and amplified by bridge amplification using the Illumina cBot machine. A paired-end 100 cycle run was used to sequence the flowcell on the HiSeq 2500 Sequencing System. Bioinformatics analysis. The Philadelphia neoadjuvant chemotherapy (NAC) data (GSE48277) were obtained from Gene Expression Omnibus (http://www.ncbi.nlm. nih.gov/geo), which consisted of microarray gene expression data of urothelial tumours before and after NAC treatment. The microarray data were quantile normalized RESEARCH LETTER and then log 2 transformed. If there were multiple probes for a gene, we used the probe with median expression value for GSEA. For the RNA-seq data analysis, the reads were trimmed from the both ends to 90 nucleotides, and then mapped to the human genome (UCSC hg19) using Tophat with NCBI RefSeq genes as the reference and up to two possible mismatches. To reduce possible biases caused by RT-PCR, read duplicates were removed using samtools. HTseq (http://www-huber.embl.de/users/ anders/HTSeq) was used to determine the number of reads falling in the known genes. The counts that indicate gene expression values were normalized to have the same total counts for each sample. The normalized counts were log 2 transformed and 1 was added to read counts to avoid log 2 transformation of zeros. Genes with small expression value (count , 6) for all samples were not used for GSEA. The wound response gene signature (GO:0009611-response to wounding) was obtained from Amigo (http://amigo.geneontology.org) consisting of 1,163 genes. Statistical analysis. All statistical analyses were performed using GraphPad Prism (GraphPad Software) and included two-tailed Student's t-test or one-way ANOVA followed by Dunnett's test for comparing the means of two or multiple groups, respectively. P , 0.05 was considered statistically significant. No formal randomization was used in any experiment; for in vivo experiments animals were unbiasedly assigned into different treatment groups. Group allocation and outcome assessment was not performed in a blinded manner. No animals or samples were excluded from data analysis. On the basis of our preliminary results, we estimated that the tumour sizes in the GC treatment group are about 200 mm 3 and we expected celecoxib plus GC combination treatment would reduce the tumour size to 80-100 mm 3 . With an estimated standard deviation of 50 mm 3 within group, we expected to have at least 80% power to detect differences of tumour volume (a 5 0.05, two-tailed t-test) using a sample size of 6 mice in each group. For in vivo experiments performed with patient-derived tumour cells, the sample size was dependent on the number of viable cells isolated upon tumour dissociation. Generally, at least six tumours were analysed for each group tested. In each set of data analysis, estimate variation is indicated in each figure as s. T4a  HG  TCC 1  T4a  HG  TCC  N3  11  -+   2  67  F  MVAC  T3  HG  TCC  T3b  HG  TCC  N0  12  -+   3 PDX  49  M  GC  T3b  HG  TCC   1   T3b  HG  TCC 4  N0  17  -+   4  49  F  GC  T4  HG  TCC  T4a  HG  TCC 1  N2  31 cancer cells (n 5 6 per group). All data represent mean 6 s.e.m. Box plots in b show twenty-fifth to seventy-fifth percentiles, with line indicating the median and whiskers indicating the smallest and the largest values. *P , 0.05; **P , 0.01; ***P , 0.001 (two-tailed Student's t-test). Scale bar, 100 mm. RESEARCH LETTER
LETTER RESEARCH
